Skip to content
10-Q

Quarterly Report

Solid Biosciences Inc. SLDB

0000950170-24-096130

← back to feed
Filed
Aug 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 9, 2024 38.6M sh
Current Liabilities Q2 2024 · Jun 30, 2024 $14.69M
Current Liabilities Q2 2024 · Dec 31, 2023 $14.52M
Total Liabilities Q2 2024 · Jun 30, 2024 $37.74M
Total Liabilities Q2 2024 · Dec 31, 2023 $38.46M
Current Assets Q2 2024 · Jun 30, 2024 $197.61M
Current Assets Q2 2024 · Dec 31, 2023 $129.73M
Total Assets Q2 2024 · Jun 30, 2024 $230.98M
Total Assets Q2 2024 · Dec 31, 2023 $164.94M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $74.02M
Cash And Equivalents Q2 2024 · Jun 30, 2023 $91.57M
Shares Diluted Q2 2024 · Jun 30, 2023 19.66M sh
Shares Diluted Q2 2024 · Jun 30, 2023 19.62M sh
Capex Q2 2024 · Jun 30, 2023 $1.04M
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$55.46M
Stockholders Equity Q2 2024 · Jun 30, 2023 $163.73M
Stockholders Equity Q2 2024 · Mar 31, 2023 $183.79M
Stockholders Equity Q2 2024 · Dec 31, 2022 $211.67M
Eps Diluted Q2 2024 · Jun 30, 2023 −$1.25
Eps Diluted Q2 2024 · Jun 30, 2023 −$2.79
Eps Basic Q2 2024 · Jun 30, 2023 −$1.25
Eps Basic Q2 2024 · Jun 30, 2023 −$2.79
Sga Expense Q2 2024 · Jun 30, 2023 $7.13M
Sga Expense Q2 2024 · Jun 30, 2023 $14.53M
Rd Expense Q2 2024 · Jun 30, 2023 $19.78M
Rd Expense Q2 2024 · Jun 30, 2023 $44.41M
Operating Income Q2 2024 · Jun 30, 2023 −$26.84M
Operating Income Q2 2024 · Jun 30, 2023 −$58.87M